Fluvoxamine (selective serotonin reuptake inhibitor) binds to the sigma-1 receptor in immune cells, resulting in reduced production of inflammatory cytokines and inflammatory genes. From The Medical letter published on the 3^rd of May 2021, sigma-1 agonism inhibits SARS-CoV-2 replication. fluvoxamine theoretically prevents the development of life-threatening cytokine storm and acute respiratory distress syndrome in coronavirus COVID-19.